Newer cytotoxic agents: Attacking cancer broadly

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1610-1617

  Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPOTHILONE A; OXALIPLATIN; PACLITAXEL; PLATINUM; SATRAPLATIN; TUBULIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GENE TARGETING; HUMAN; MICROTUBULE; MITOSIS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG THERAPY; HUMANS; MITOSIS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUBULIN;

EID: 41549130929     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2249     Document Type: Review

References (63)

1. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZ2171 in lung cancer. Clin Cancer Res 2007;13:s4617-22.
2. Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol 2007;62:93-104.
3. Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007;12:325-30.
4. George DJ. Phase 2studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin Cancer Res 2007;13:753-7s.
5. Dziadzuiuszko R, Hirsch FR, Varella-Garcia M, Bunn PA, Jr. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization-why, when, and how? Clin Cancer Res 2006;12:4409-15s.
6. Sankhala KK, Papadopoulos KP. Future options for imatinib mesilate-resistant tumors. Expert Opin Investig Drugs 2007;16:1549-60.
7. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8.
8. Wang H, Han H, Mousses S, Von Hoff DD. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol 2006;33:513-20.
9. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
10. Nicolau M, Tibshirani R, Borresen-Dale AL, Jeffrey SS. Disease-specific genomic analysis: identifying the signature of pathologic biology. Bioinformatics 2007;23:957-65.
11. Chanock SJ, Burdett L, Yeager M, et al. Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res 2007;9:R5.
12. Yosef N, Yakhini Z, Tsalenko A, et al. A supervised approach for identifying discriminating genotypes patterns and its application to breast cancer data. Bioinformatics 2007;23:e91-8.
13. Choy H, Park C, Yao M. Current status and future prospect for satraplatin: an oral platinum analogue. Clin Cancer Res 2008;14:1618-23.
14. Highley MS, Calvert AH. Clinical experience with cisplatin and carboplatin In: Kelland LR, Farrell N, editors. Platinum-Based Drugs in Cancer Therapy. Totowa (NJ); Humana Press, Inc.: 2000. p.171-94.
15. Crul M, van Waardenburg RCAM, Beijen JH, Schellens JHM. DNA-based drug interactions of cisplatin. Cancer Treat Rev 2002;28:291-303.
16. Chaney SG, Vaisman A. Specificity of platinum-DNA adduct repair. J Inorg Biochem 1999;77:71-81.
17. Raymond E, Faivre S, Chaney S, Woynarowski S, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-35.
18. Li CM. The role of mismatch repair in DNA-damage-induced apoptosis. Oncol Res 1999;11:393-400.
19. Lage H, Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 1999;125:156-65.
20. Manic S, Gatti L, Carenini N, et al. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003;3:21-9.
21. Fink D, Nebel S, Aebi S, et al. The role of mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
22. Fink D, Nebel S, Norris PS, et al. Enrichment of DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 1998;77:741-6.
23. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512-7.
24. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-8.
25. Selvakumaran M, Pisarick DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003;63:1311-6.
26. Sancar A. Excision repair invades the territory of mismatch repair. Nat Genet 1999;21:247-9.
27. Alt A, Lammens K, Chiocchini C, et al. Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase mu. Science 2007;318:967-70.
28. Albertella MR, Green CM, Lehmann AR, O'Connor MJ. A role for polymerase η in the cellular tolerance to cisplatin-induced damage. Cancer Res 2005;65:9799-806.
29. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20.
30. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007;7:899-910.
31. Beale P, Judson I, O'Donnell A, et al. A phase I clinical trial and pharmacological study of diamminedichloro( 2-methylpyridine) platinum II (AMD473). Br J Cancer 2003;88:1128-34.
32. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy. New York: Lippincott-Raven Publishers; 1996. p. 263-96.
33. Bhat KMR, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007;13:2849-54.
34. Johnson IS, Armostrong JG, Gorman M, Burnett JP, Jr. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1967;23:1390-427.
35. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991;51:2212-22.
36. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
37. Hinnen P, Eskens FALM. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-65.
38. Bennouna J, Delord JP, Campone M, Pinel MC. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 2008;14:1610-7.
39. Stierle A, Strobel G, Stierle D. Taxol and taxane production by Taxomyces andreannae, an endophytic fungus of Pacific yew. Science 1993;260:214-8.
40. Ringel I, Horwitz SB. Studies with RP56967 (Taxotere): a semisynthetic analog of taxol. J Natl Cancer Inst 1991;83:288-91.
41. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008;1643-9.
42. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007;12:271-80.
43. Nettles JH, Li H, Cornett B. The binding mode of epothilone A on a, β-tubulin by electron crystallography. Science 2004;305:866-9.
44. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremophor-EL-free formulation of paclitaxel. Nanomedicine 2007;2:415-23.
45. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007;7:919-43.
46. Perez EA. Novel enhanced delivery taxanes: an update. Semin Oncol 2007;34(Suppl):1-5.
47. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV. Aurora A, meiosis and mitosis. Biol Cell 2003;96:215-29.
48. Marumoto T, Honda S, Hara T, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-95.
49. Mora-Bermudez F, Gerlich D, Ellenberg J. Maximal chromosomes compaction occurs by axial shortening in anaphase and depends on aurora kinase. Nat Cell Biol 2007;9:822-31.
50. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr., Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1624-33.
51. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:2794-7.
52. Li JJ, Li SA. Mitotoic kinases: the key to duplication, segregation and cytokinesis errors, chromosome instability and oncogenesis. Pharmacol Ther 2006;111:974-84.
53. Fukasawa K. Oncogenes and tumor supressors take on centrosomes. Nat Rev Cancer 2007;7:911-24.
54. Fukasawa K. Centrosome amplification, chromosome instability and cancer development. Cancer Lett 2005;230:6-19.
55. Katayma H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces MDM2-mediated destabilization and inhibition of p53. Nat Genet 2004;36:55-62.
56. Agnese V, Bazan V, Fiorentino FP, et al. Russo A. The role of aurora-A inhibitors in cancer therapy. Ann Oncol 2007;18(suppl 6):47-52.
57. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
58. Adams J. The development of proteasome inhibitors as anticancer agents. Cancer Cell 2004;5:417-21.
59. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
60. Landis-Piwowar KR, Milacic V, Chen D, et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 2006;9:263-73.
61. Demarchi F, Brancolini C. Altering protein turnover in tumor cells: new opportunity for anticancer therapies. Drug Resist Updat 2005;8:359-68.
62. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1634-42.
63. Nikiforov MA, Riblett MB, Tang W-H, et al. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 2007;104:19488-93.